Drug developer Suma Krishnan was 51 when she had the idea for a topical gene therapy to treat a rare and terrible skin disorder, called dystrophic epidermolysis bullosa, in which the skin becomes as ...

Earnings call Crystal Biotech reported Q2 2025 revenue of $96M, up 9% sequentially, driven by patient restarts and early salesforce expansion. EPS came in at $1.29 diluted, marking two years of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A rare skin disorder that leads to fragile skin susceptible to frequent wounds and blisters now has its first FDA-approved therapy, a topically applied gel that facilitates healing. The Krystal ...

In his 21 plus years of professional experience, Krishnan has been solving complex solution architecture problems around data warehousing and business intelligence for Fortune 1000 clients across the ...

PITTSBURGH — Forbes’s 2025 50 Over 50 list features local founder Suma Krishnan. Krishnan is the co-founder and president of Krystal Biotech Inc., (NASDAQ: KRYS) a South Side-based company whose ...

Thank you for standing by, and welcome to the Krystal Biotech Q2 2025 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded. I would now like to hand the ...